Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise [View article] Tuesday 12 February 2019 20:07 Categories: Immunobody Media Coverage Modi-1 Modi-2 SCIB1 SCIB2 Year - 2019 Previous Post << >> Next Post